[1] [2] They work by mimicking the action of naturally occurring GLP-1, an incretin hormone released by the intestine in response to food intake
A recent multicenter retrospective study published in 2024 further validated tirzepatides real-world efficacy in OSAS management
This page is informational only, is not medical advice, and does not guarantee any specific outcome
It should not be used concurrently with other GLP-1 receptor agonists
Start the provider review Evidence check A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner
Many gastrointestinal side effects may decrease as treatment continues, but there is no guaranteed week when they disappear